This Kalorama Information report focuses on current and emerging immunomodulators for cancer. The report covers both current and emerging cancer immunomodulators in detail.
The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. These include bladder, breast, colorectal, head/neck, kidney, lung, ovarian, pancreatic, and prostate cancers, as well as leukemia, lymphoma, melanoma, multiple myeloma, and neuroblastoma.
The current market segment provides an overview, descriptions of products on the market, market estimates and forecasts, and competitive analysis of leading providers. The emerging market segment provides an overview, descriptions of products in development, market forecasts, and forecasted competitive analysis for 2008. The report also includes current issues and trends affecting the industry.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2003. Historical data was provided for the years 2001 and 2002, with forecast data provided for 2004 through 2008. Compound annual growth rates (CAGRs) are provided for the 2001-2003, 2003-2008 and 2001-2008 periods for each industry segment covered. Competitive analysis is provided for the year 2003 for the current market and projected competitive analysis for 2008 for the emerging market. The projected competitive analysis for 2008 was based on products in late stage development, probability of approval and marketing, and demographic trends.